Yazar "Basturk, Abdulkadir" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Convalescent plasma therapy in patients withCOVID-19
    (Wiley, 2020) Yigenoglu, Tugce Nur; Hacibekiroglu, Tuba; Berber, Ilhami; Dal, Mehmet Sinan; Basturk, Abdulkadir; Namdaroglu, Sinem; Korkmaz, Serdal
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID-19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID-19. CP may be an adjunctive treatment option to the anti-viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200-600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID-19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.
  • Küçük Resim Yok
    Öğe
    A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura
    (Pergamon-Elsevier Science Ltd, 2021) Basturk, Abdulkadir; Sayin, Serhat; Erkurt, Mehmet Ali; Sarici, Ahmet; Ekinci, Omer; Kum, Asli; Berber, Ilhami
    Immune Thrombocytopenia (ITP) is an autoimmune disease characterized by thrombocytopenia and skin and mucosal bleeding. In patients with an indication for treatment, corticosteroids, intravenous immunoglobulin (IVIg) and anti-D are recommended as the first line, while splenectomy, thrombopoietin receptor agonists or rituximab are recommended second line options. Approximately 10 % of adult patients with ITP fall into the chronic refractory ITP group. Therapeutic plasma exchange (TPE) has generally been tested in patients with refractory ITP, who have failed to respond to conventional treatments, in case of bleeding or prior to surgical interventions. It has been stated that elimination of the antibodies that are held responsible in the pathogenesis of the disease has an effective role in the treatment. In this article, we present the results of 17 patients, who underwent TPE for refractory ITP, together with the literature data.
  • Küçük Resim Yok
    Öğe
    A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
    (Galenos Publ House, 2023) Serin, Istemi; Dogu, Mehmet Hilmi; Ekinci, Omer; Cagliyan, Gulsum Akgun; Basturk, Abdulkadir; Aras, Merih Reis; Demircioglu, Sinan
    Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: >= 35%) by imaging and control of hematocrit levels (<= 45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
  • Küçük Resim Yok
    Öğe
    SEVERE HYPERBILIRUBINEMIA DURING FAMILYAL MEDITERRANEAN FEVER ATTACK IN PATIENTS WITH GILBERT'S SYNDROME
    (Istanbul Univ, Faculty Medicine, Publishing Office, 2016) Kutlu, Orkide; Keskin, Muharrem; Basturk, Abdulkadir; Ecirli, Samil; Bilgic, Yilmaz; Fisekci Oktar, Sevil
    Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterized by fever and accompanying attacks of serositis. Cytokines such as IL-6, TNF-alpha, IL-1 beta are known to play an active role in FMF pathogenesis. Gilbert's syndrome, is a clinical condition that results indirect hyperbilirubinemia during febrile illness, surgery, vomiting and prolonged fasting period because of inhibition of UDP-glucuronide transferase activity. Increased bilirubin levels during FMF attack is caused suppression of UDP-glucuronide transferase activity by cytokines involved in the pathogenesis of FMF. Here, we report a patient who had serious indirect bilirubin elevation during an attack of FMF.